Literature DB >> 26780494

WHO grade 1 meningioma recurrence: Are location and Simpson grade still relevant?

Mathew J Gallagher1, Michael D Jenkinson2, Andrew R Brodbelt3, Samantha J Mills4, Emmanuel Chavredakis5.   

Abstract

OBJECTIVE: To examine whether Simpson grade and pathology location are still predictors of recurrence/progression free survival (RPFS) in WHO grade 1 cranial meningiomas.
METHODS: A retrospective case series of all WHO grade 1 cranial meningiomas undergoing surgical resection at our institution between 2002 to 2007 was performed. Demographic and outcome data included: Simpson grade, extent of resection [gross total (Simpson 1-3) and sub total (Simpson 4-5)], tumour location, timing of post-operative imaging and outpatient review, time to recurrence and subsequent management. Statistical analysis was by Kaplan-Meier survival curves.
RESULTS: 145 cases were included of which 75% were female, with an overall median age of 55 years. 24% had parasagittal, 23% convexity and 53% skull base meningioma. 21% had a grade 1 Simpson resection, 43% grade 2, 35% grade 4 and 1% grade 5. The median follow up period was 60 months with a median 5.5 outpatient appointments and 5 post-operative imaging studies. 10 cases (6.9%) had recurrence/progression at a median period of 42 months. Of these, 4 remained under active surveillance, 3 received stereotactic radiosurgery and 3 were treated with fractionated radiotherapy. 5 year recurrence/progression free survival (RPFS) for Simpson grade 1 was 96.8%, 2: 100%, 4: 82.4% and 5: 0%. Simpson grade (p=0.01) and gross total/sub total resection (p=0.001) were significant predictors of RPFS. Meningioma location was not a significant predictor of RPFS (p-value 0.836).
CONCLUSION: Simpson grade remains a significant predictor of RPFS in WHO grade 1 meningioma surgery. However, tumour location was not significant in this series. We advocate different post-operative imaging surveillance protocols depending on gross total or sub total surgical resection.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Location; Meningioma; Outcome; Recurrence; Simpson grade

Mesh:

Year:  2016        PMID: 26780494     DOI: 10.1016/j.clineuro.2016.01.006

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  25 in total

1.  Meningiomas: skull base versus non-skull base.

Authors:  Torstein R Meling; Michele Da Broi; David Scheie; Eirik Helseth
Journal:  Neurosurg Rev       Date:  2018-04-07       Impact factor: 3.042

2.  Meningioma recurrence rates following treatment: a systematic analysis.

Authors:  Victor Lam Shin Cheung; Albert Kim; Arjun Sahgal; Sunit Das
Journal:  J Neurooncol       Date:  2017-11-15       Impact factor: 4.130

3.  Resected WHO grade I meningioma and predictors of local control.

Authors:  Kamila Nowak-Choi; Joshua D Palmer; James Casey; Ameet Chitale; Ingrid Kalchman; Elizabeth Buss; Scott W Keith; Sarah E Hegarty; Mark Curtis; Charalambos Solomides; Wenyin Shi; Kevin Judy; David W Andrews; Christopher Farrell; Maria Werner-Wasik
Journal:  J Neurooncol       Date:  2021-01-09       Impact factor: 4.130

4.  Value of K i -67 Labeling Index in Predicting Recurrence of WHO Grade I Cranial Base Meningiomas.

Authors:  Jose Gabrielle Matias; Ignacio Jusue-Torres; Brendan Martin; Ankush Bajaj; Ewa Borys; Edward Melian; Kevin Barton; Douglas E Anderson; Vikram C Prabhu
Journal:  J Neurol Surg B Skull Base       Date:  2018-09-06

5.  The Simpson grading in meningioma surgery: does the tumor location influence the prognostic value?

Authors:  Kira Marie Voß; Dorothee Cäcilia Spille; Cristina Sauerland; Eric Suero Molina; Caroline Brokinkel; Werner Paulus; Walter Stummer; Markus Holling; Astrid Jeibmann; Benjamin Brokinkel
Journal:  J Neurooncol       Date:  2017-05-19       Impact factor: 4.130

6.  Consensus core clinical data elements for meningiomas (v2021.1).

Authors:  Farshad Nassiri; Justin Z Wang; Karolyn Au; Jill Barnholtz-Sloan; Michael D Jenkinson; Kate Drummond; Yueren Zhou; James M Snyder; Priscilla Brastianos; Thomas Santarius; Suganth Suppiah; Laila Poisson; Francesco Gaillard; Mark Rosenthal; Timothy Kaufmann; Derek S Tsang; Kenneth Aldape; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2022-05-04       Impact factor: 13.029

7.  Advances in multidisciplinary therapy for meningiomas.

Authors:  Priscilla K Brastianos; Evanthia Galanis; Nicholas Butowski; Jason W Chan; Ian F Dunn; Roland Goldbrunner; Christel Herold-Mende; Franziska M Ippen; Christian Mawrin; Michael W McDermott; Andrew Sloan; James Snyder; Ghazaleh Tabatabai; Marcos Tatagiba; Joerg C Tonn; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Michael D Jenkinson; David R Raleigh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

8.  Molecular and translational advances in meningiomas.

Authors:  Suganth Suppiah; Farshad Nassiri; Wenya Linda Bi; Ian F Dunn; Clemens Oliver Hanemann; Craig M Horbinski; Rintaro Hashizume; Charles David James; Christian Mawrin; Houtan Noushmehr; Arie Perry; Felix Sahm; Andrew Sloan; Andreas Von Deimling; Patrick Y Wen; Kenneth Aldape; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

9.  Prognostic significance of preoperative neutrophilia on recurrence-free survival in meningioma.

Authors:  Shirin Karimi; Manav V Vyas; Lior Gonen; Raha Tabasinejad; Quinn T Ostrom; Jill Barnholtz-Sloan; Suganth Suppiah; Gelareh Zadeh; Kenneth Aldape
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

10.  The growth rate and clinical outcomes of radiation induced meningioma undergoing treatment or active monitoring.

Authors:  Conor S Gillespie; Abdurrahman I Islim; Basel A Taweel; Christopher P Millward; Siddhant Kumar; Nitika Rathi; Shaveta Mehta; Brian J Haylock; Nicola Thorp; Catherine E Gilkes; David D A Lawson; Samantha J Mills; Emmanuel Chavredakis; Jibril Osman Farah; Andrew R Brodbelt; Michael D Jenkinson
Journal:  J Neurooncol       Date:  2021-04-22       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.